These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20555096)

  • 1. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guidelines for the management.
    Mandalà M; Falanga A; Roila F;
    Ann Oncol; 2010 May; 21 Suppl 5():v274-6. PubMed ID: 20555096
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of Cancer-Associated Venous Thromboembolism in the Emergency Department.
    Nene RV; Coyne CJ
    Ann Emerg Med; 2017 Jun; 69(6):768-776. PubMed ID: 28169053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention and treatment of venous thromboembolism in patients with cancer].
    Struve S; Wendtner CM
    Dtsch Med Wochenschr; 2012 Oct; 137(40):2007-9. PubMed ID: 22987155
    [No Abstract]   [Full Text] [Related]  

  • 4. [Secondary prevention of venous thromboembolism in patients with cancer].
    Meyer G
    Rev Prat; 2011 Nov; 61(9):1249-51. PubMed ID: 22308809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LMWH in cancer patients with renal impairment - better than warfarin?
    Bauersachs RM
    Thromb Res; 2016 Apr; 140 Suppl 1():S160-4. PubMed ID: 27067971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Thoughts about thromboembolic events prophylaxis in cancer patients].
    Pikó B; Kremer IM; Rahoty P; Bassam A; Dimák S; Kis A; Csiffári M; Rus-Gal P; Szabó Z; Veréb B; Zsilak J
    Magy Onkol; 2011 Sep; 55(3):164-9. PubMed ID: 21918741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Korean guidelines for the prevention of venous thromboembolism.
    Bang SM; Jang MJ; Oh D; Kim YK; Kim IH; Yoon SS; Yoon HJ; Kim CS; Park S;
    J Korean Med Sci; 2010 Nov; 25(11):1553-9. PubMed ID: 21060742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management.
    Mandalà M; Labianca R;
    Thromb Res; 2010 Apr; 125 Suppl 2():S117-9. PubMed ID: 20433989
    [No Abstract]   [Full Text] [Related]  

  • 9. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin K Antagonists Compared to Low-Molecular-Weight Heparins for Treatment of Cancer-Associated Venous Thromboembolism: An Observational Study in Routine Clinical Practice. An Observational Study in Routine Clinical Practice.
    den Exter PL; Hooijer J; van der Hulle T; van Oosten JP; Dekkers OM; Klok FA; Huisman MV
    Thromb Haemost; 2017 Nov; 117(11):2163-2167. PubMed ID: 28981552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticoagulant use in cancer patients.
    Trujillo-Santos J; Monreal M
    Expert Opin Pharmacother; 2011 Feb; 12(3):351-62. PubMed ID: 21254944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Venous thrombo-embolic disease in cancer. Low molecular weight heparin indications].
    Nou M; Laroche JP
    J Mal Vasc; 2016 May; 41(3):197-204. PubMed ID: 27146099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials.
    Louzada ML; Majeed H; Wells PS
    Thromb Res; 2009 Apr; 123(6):837-44. PubMed ID: 18977517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of recurrent venous thromboembolism in cancer patients.
    Romualdi E; Ageno W
    Thromb Res; 2016 Apr; 140 Suppl 1():S128-31. PubMed ID: 27067966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer.
    Pritchard ER; Murillo JR; Putney D; Hobaugh EC
    J Oncol Pharm Pract; 2019 Jan; 25(1):52-59. PubMed ID: 28825375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thromboembolism--risk, prevention and therapy. Practice Guideline].
    ;
    Orv Hetil; 2009 Dec; 150(52):2335-404. PubMed ID: 20031519
    [No Abstract]   [Full Text] [Related]  

  • 17. A review of the practical advantages of low molecular weight heparin in the treatment of cancer-related venous thromboembolism.
    Rhodes S; Bond S
    Eur J Oncol Nurs; 2008 Dec; 12(5):425-9. PubMed ID: 18842458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism and prophylaxis in cancer patients.
    Paskauskas S; Pundzius J; Barauskas G
    Medicina (Kaunas); 2008; 44(3):175-81. PubMed ID: 18413983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines.
    Mandalà M; Falanga A; Roila F;
    Ann Oncol; 2011 Sep; 22 Suppl 6():vi85-92. PubMed ID: 21908511
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.
    Meyer G; Marjanovic Z; Valcke J; Lorcerie B; Gruel Y; Solal-Celigny P; Le Maignan C; Extra JM; Cottu P; Farge D
    Arch Intern Med; 2002 Aug 12-26; 162(15):1729-35. PubMed ID: 12153376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.